2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses immunotherapy for patients with EGFR-mutated lung cancer.
Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses immunotherapy for patients with EGFR-mutated lung cancer.
Looking at the subgroup analysis for all randomized clinical trials, there is no clear benefit in EGFR-mutated patients, making it difficult to decide whether to treat with immunotherapy or chemotherapy, explains Garassino.
In the ATLANTIC trial, patients with EGFR-mutated lung cancer were treated with durvalumab (Imfinzi). These patients experienced a benefit with progression-free survival and overall survival, states Garassino.
Related Content: